Humabiologics, Inc.
Humabiologics, Inc., headquartered in the United States, is a pioneering entity in the biopharmaceutical industry, specialising in the development and distribution of innovative human-derived biological products. Founded in 2015, the company has rapidly established itself as a leader in regenerative medicine, focusing on advanced cellular therapies and tissue engineering. With a commitment to quality and scientific excellence, Humabiologics offers unique products such as human amniotic membrane and umbilical cord tissue, which are utilised in various medical applications, including wound healing and orthopaedic procedures. The company’s dedication to research and development has led to significant advancements in the field, positioning it as a trusted partner for healthcare providers seeking cutting-edge solutions. Humabiologics continues to expand its operational reach, contributing to the evolving landscape of regenerative medicine.
DitchCarbon Score
How does Humabiologics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Humabiologics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Humabiologics, Inc.'s reported carbon emissions
Humabiologics, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Humabiologics has not cascaded any emissions data from a parent or related organisation, nor does it appear to be part of any industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the absence of specific emissions data or commitments, it is unclear how Humabiologics is addressing climate change or its carbon footprint. The company may need to establish clear climate commitments and reduction strategies to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Humabiologics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
